Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
1 kopie van APOE3 Christchurch-variant vertraagt autosomaal dominante ziekte van Alzheimer
aug 2024 | Dementie